miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease.
dc.contributor.author | Perez-Sanchez, Carlos | |
dc.contributor.author | Barbera Betancourt, Ariana | |
dc.contributor.author | Lyons, Paul A | |
dc.contributor.author | Zhang, Zinan | |
dc.contributor.author | Suo, Chenqu | |
dc.contributor.author | Lee, James C | |
dc.contributor.author | McKinney, Eoin F | |
dc.contributor.author | Modis, Louise K | |
dc.contributor.author | Ellson, Christian | |
dc.contributor.author | Smith, Kenneth GC | |
dc.date.accessioned | 2022-05-09T09:11:09Z | |
dc.date.available | 2022-05-09T09:11:09Z | |
dc.date.issued | 2022-05-02 | |
dc.identifier.issn | 0022-1007 | |
dc.identifier.other | 35363256 | |
dc.identifier.other | PMC8980842 | |
dc.identifier.uri | https://www.repository.cam.ac.uk/handle/1810/336820 | |
dc.description | Funder: UK National Institute of Health Research Cambridge Biomedical Research Centre | |
dc.description.abstract | MicroRNAs are critical regulators of gene expression controlling cellular processes including inflammation. We explored their role in the pathogenesis of inflammatory bowel disease (IBD) and identified reduced expression of miR-374a-5p in IBD monocytes that correlated with a module of up-regulated genes related to the inflammatory response. Key proinflammatory module genes, including for example TNFα, IL1A, IL6, and OSM, were inversely correlated with miR-374a-5p and were validated in vitro. In colonic biopsies, miR-374a-5p was again reduced in expression and inversely correlated with the same inflammatory module, and its levels predicted subsequent response to anti-TNF therapy. Increased miR-374a-5p expression was shown to control macrophage-driven inflammation by suppressing proinflammatory mediators and to reduce the capacity of monocytes to migrate and activate T cells. Our findings suggest that miR-374a-5p reduction is a central driver of inflammation in IBD, and its therapeutic supplementation could reduce monocyte-driven inflammation in IBD or other immune-mediated diseases. | |
dc.description.sponsorship | This study was funded via the GSK/Cambridge Strategic Alliance Varsity Funding Program, Wellcome (project grant 094227/Z/10/Z and Investigator Award 200871/Z/16/Z), the European Union H2020 project SYSCID (grant 733100), the UK Medical Research Council (program grant MR/L019027), and the UK National Institute of Health Research Cambridge Biomedical Research Centre. | |
dc.language | eng | |
dc.publisher | Rockefeller University Press | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.source | nlmid: 2985109R | |
dc.source | essn: 1540-9538 | |
dc.subject | Colitis | |
dc.subject | Humans | |
dc.subject | Inflammatory Bowel Diseases | |
dc.subject | MicroRNAs | |
dc.subject | Monocytes | |
dc.subject | Tumor Necrosis Factor Inhibitors | |
dc.title | miR-374a-5p regulates inflammatory genes and monocyte function in patients with inflammatory bowel disease. | |
dc.type | Article | |
dc.date.updated | 2022-05-09T09:11:08Z | |
prism.issueIdentifier | 5 | |
prism.publicationName | Journal of Experimental Medicine | |
prism.volume | 219 | |
dc.identifier.doi | 10.17863/CAM.84239 | |
dcterms.dateAccepted | 2022-02-17 | |
rioxxterms.versionofrecord | 10.1084/jem.20211366 | |
rioxxterms.version | VoR | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.contributor.orcid | Lyons, Paul [0000-0001-7035-8997] | |
dc.contributor.orcid | McKinney, Eoin [0000-0003-3516-3072] | |
dc.contributor.orcid | Smith, Kenneth [0000-0003-3829-4326] | |
dc.identifier.eissn | 1540-9538 | |
pubs.funder-project-id | Medical Research Council (MR/L019027/1) | |
pubs.funder-project-id | European Commission Horizon 2020 (H2020) Societal Challenges (733100) | |
cam.issuedOnline | 2022-04 |
Files in this item
This item appears in the following Collection(s)
-
Jisc Publications Router
This collection holds Cambridge publications received from the Jisc Publications Router